crizanlizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5365 1690318-25-2

Description:

MoleculeDescription

Synonyms:

  • crizanlizumab
  • crizanlizumab-tmca
  • adavkeo
  • SEG101
  • SelG1
  • NVP-LXI262
Crizanlizumab-tmca is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks interactions with its ligands including P-selectin glycoprotein ligand 1. Binding P-selectin on the surface of the activated endothelium and platelets blocks interactions between endothelial cells, platelets, red blood cells, and leukocytes.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
12.50 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Nov. 15, 2019 FDA NOVARTIS PHARMS CORP
Oct. 28, 2020 EMA NOVARTIS EUROPHARM LIMITED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sickle cell anaemia with crisis 630.48 53.05 100 786 7197 90620364
Pain 162.27 53.05 106 780 996235 89631326
Acute chest syndrome 115.04 53.05 18 868 1130 90626431
Back pain 96.23 53.05 51 835 317124 90310437
Infusion related reaction 73.07 53.05 47 839 416733 90210828

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sickle cell anaemia with crisis 553.30 60.34 87 440 4803 42616005
Pain 125.44 60.34 60 467 244788 42376020
Back pain 101.31 60.34 44 483 141732 42479076
Acute chest syndrome 97.90 60.34 16 511 1049 42619759
Infusion related reaction 89.73 60.34 32 495 60774 42560034
Chest pain 70.09 60.34 34 493 139496 42481312

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sickle cell anaemia with crisis 676.23 49.32 110 949 9435 110578805
Pain 164.94 49.32 105 954 954850 109633390
Acute chest syndrome 160.59 49.32 26 1033 2077 110586163
Back pain 135.28 49.32 67 992 370929 110217311
Infusion related reaction 121.80 49.32 63 996 381099 110207141
Chest pain 83.47 49.32 49 1010 376326 110211914
Pain in extremity 67.10 49.32 47 1012 487071 110101169

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B06AX01 BLOOD AND BLOOD FORMING ORGANS
OTHER HEMATOLOGICAL AGENTS
OTHER HEMATOLOGICAL AGENTS
Other hematological agents
FDA MoA N0000194031 P-Selectin Blockers
FDA EPC N0000194032 Selectin Blocker
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:233423 antifibrotic agent

Related Drugs by ATC class:

B06AX Other hematological agents 2 drugs
mitapivatvoxelotor

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Vaso-occlusive crisis in sickle cell disease indication 769167005




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
P-selectin Adhesion INHIBITOR IC50 5.59 DRUG LABEL DRUG LABEL

External reference:

IDSource
4038967 VANDF
4038968 VANDF
CHEBI:757186 CHEBI
CHEMBL4297734 ChEMBL_ID
D11480 KEGG_DRUG
C000614139 MESH_SUPPLEMENTAL_RECORD_UI
10550 IUPHAR_LIGAND_ID
DB15271 DRUGBANK_ID
830102002 SNOMEDCT_US
830160007 SNOMEDCT_US
C4524703 UMLSCUI
10316 INN_ID
37673 MMSL
37674 MMSL
d09436 MMSL
018193 NDDF
L7451S9126 UNII
2262279 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ADAKVEO HUMAN PRESCRIPTION DRUG LABEL 1 0078-0883 INJECTION 10 mg INTRAVENOUS BLA 29 sections